NASDAQ:SLN Silence Therapeutics (SLN) Stock Forecast, Price & News $5.40 -0.31 (-5.43%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$5.20▼$5.8150-Day Range$4.61▼$9.1952-Week Range$4.55▼$17.99Volume34,884 shsAverage Volume60,763 shsMarket Capitalization$161.62 millionP/E RatioN/ADividend YieldN/APrice Target$44.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Silence Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside728.7% Upside$44.75 Price TargetShort InterestHealthy0.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.83) to ($1.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector449th out of 983 stocksPharmaceutical Preparations Industry215th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.75, Silence Therapeutics has a forecasted upside of 728.7% from its current price of $5.40.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.08% of the float of Silence Therapeutics has been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 36.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLN. Previous Next 3.4 News and Social Media Coverage News SentimentSilence Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest3 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Silence Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to decrease in the coming year, from ($1.83) to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 8.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Silence Therapeutics (NASDAQ:SLN) StockSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Read More Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Stock News HeadlinesMay 24, 2023 | americanbankingnews.comWilliam Blair Comments on Silence Therapeutics plc's Q2 2023 Earnings (NASDAQ:SLN)May 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Services Companies: Silence Therapeutics (SLN), Paypal Holdings (PYPL) and Liberty Global C (LBTYK)June 2, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 8, 2023 | msn.comSilence Therapeutics overweight at Morgan Stanley on RNAi platformMay 8, 2023 | markets.businessinsider.comAnalysts Conflicted on These Services Names: Silence Therapeutics (SLN) and Planet Fitness (PLNT)May 8, 2023 | americanbankingnews.comMorgan Stanley Begins Coverage on Silence Therapeutics (NASDAQ:SLN)March 31, 2023 | americanbankingnews.comSilence Therapeutics plc (NASDAQ:SLN) Forecasted to Post FY2025 Earnings of ($2.04) Per ShareMarch 29, 2023 | msn.comAmerican Depositary Receipts of European Equities Rise As Banking Sector Worries EaseJune 2, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. March 29, 2023 | finance.yahoo.comSilence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease DaysMarch 21, 2023 | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Stock Rating Reaffirmed by HC WainwrightMarch 20, 2023 | insidermonkey.comSilence Therapeutics plc (NASDAQ:SLN) Q4 2022 Earnings Call TranscriptMarch 16, 2023 | nypost.comTweet from Aaron Rodgers’ account prompts confusion after breaking silenceMarch 15, 2023 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2022 ResultsMarch 15, 2023 | businesswire.comSilence Therapeutics Reports Fourth Quarter and Full Year 2022 ResultsMarch 13, 2023 | seekingalpha.comSLN Silence Therapeutics plcMarch 6, 2023 | theguardian.comCovert cameras and alleged hacking: how bust payments company Wirecard ‘hired spies and lawyers to silence critics’March 6, 2023 | finance.yahoo.comSilence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?March 2, 2023 | businesswire.comSilence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023January 19, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer TherapeuticsJanuary 4, 2023 | finance.yahoo.comSilence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?January 3, 2023 | finance.yahoo.comSilence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 6, 2022 | msn.comWhat’s Changed Since TIME Named the ‘Silence Breakers’ Person of the YearNovember 7, 2022 | msn.com‘The Opposite of Fear Is Love’: Christos Passalis on Grief and Healing in Thessaloniki Competition Title ‘Silence 6-9’November 5, 2022 | finance.yahoo.comSilence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual MeetingOctober 7, 2022 | finance.yahoo.comSilence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage StudySeptember 22, 2022 | latimes.comColumn: Amid the pageantry and corgis, what made the queen’s funeral extraordinary was silenceSee More Headlines SLN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLN Company Calendar Last Earnings3/15/2023Today6/02/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees105Year Founded1999Price Target and Rating Average Stock Price Forecast$44.75 High Stock Price Forecast$80.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+728.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,080,000.00 Net Margins-185.71% Pretax Margin-218.65% Return on Equity-254.24% Return on Assets-41.68% Debt Debt-to-Equity Ratio0.01 Current Ratio4.71 Quick Ratio4.71 Sales & Book Value Annual Sales$21.65 million Price / Sales7.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book8.06Miscellaneous Outstanding Shares29,930,000Free Float29,045,000Market Cap$161.62 million OptionableNot Optionable Beta0.74 Social Links Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 56)MBA, Pres, CEO & Exec. Director Comp: $481.48kMs. Rhonda L. Hellums (Age 50)Chief Financial Officer Comp: $270.1kDr. Giles V. Campion M.D. (Age 68)Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director Comp: $617.91kMs. Gem Gokmen HopkinsHead of IR & Corp. CommunicationsDr. John Strafford Ph.D.Sr. VP of Bus. Devel., Alliance Management & New Product Devel.Mr. Jørgen WittendorffSr. VP & Head of ManufacturingDr. Barbara A. Ruskin J.D. (Age 62)Ph.D., Sr. VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd Ph.D. (Age 60)Sr. VP of Regulatory Affairs & Quality Assurance Dr. Marie Wikstrom Lindholm Ph.D.Sr. VP & Head of Molecular DesignMore ExecutivesKey CompetitorsCitius PharmaceuticalsNASDAQ:CTXRZevra TherapeuticsNASDAQ:ZVRAADC TherapeuticsNYSE:ADCTKinnate BiopharmaNASDAQ:KNTESelecta BiosciencesNASDAQ:SELBView All CompetitorsInstitutional OwnershipAXA S.A.Sold 125,250 shares on 5/15/2023Ownership: 1.726%Schonfeld Strategic Advisors LLCBought 11,600 shares on 5/15/2023Ownership: 0.137%View All Institutional Transactions SLN Stock - Frequently Asked Questions Should I buy or sell Silence Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares. View SLN analyst ratings or view top-rated stocks. What is Silence Therapeutics' stock price forecast for 2023? 3 brokerages have issued twelve-month price objectives for Silence Therapeutics' shares. Their SLN share price forecasts range from $20.00 to $80.00. On average, they predict the company's share price to reach $44.75 in the next twelve months. This suggests a possible upside of 728.7% from the stock's current price. View analysts price targets for SLN or view top-rated stocks among Wall Street analysts. How have SLN shares performed in 2023? Silence Therapeutics' stock was trading at $15.25 at the start of the year. Since then, SLN stock has decreased by 64.6% and is now trading at $5.40. View the best growth stocks for 2023 here. Are investors shorting Silence Therapeutics? Silence Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 22,400 shares, a decline of 36.7% from the April 30th total of 35,400 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are sold short. View Silence Therapeutics' Short Interest. When is Silence Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our SLN earnings forecast. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) announced its earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.91. The firm had revenue of $5.59 million for the quarter, compared to analyst estimates of $36.30 million. Silence Therapeutics had a negative net margin of 185.71% and a negative trailing twelve-month return on equity of 254.24%. What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN." Who are Silence Therapeutics' major shareholders? Silence Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include AXA S.A. (1.73%) and Schonfeld Strategic Advisors LLC (0.14%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately $5.40. How much money does Silence Therapeutics make? Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $161.62 million and generates $21.65 million in revenue each year. The company earns $-50,080,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How many employees does Silence Therapeutics have? The company employs 105 workers across the globe. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900. This page (NASDAQ:SLN) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.